Cobalt chromium coronary stent market entry in Europe with New CoCr StentGlobal Therapeutics.

Cobalt chromium coronary stent market entry in Europe with New CoCr StentGlobal Therapeutics, cardiology Cook Medical has CE marked for a new cobalt-chromium bare-metal coronary stent that executives believe that the demand for non – fill drug -eluting coronary stent with interventional cardiologists, the company announced today. The device, the Global Therapeutics GT Coronary Stent System is now available in the European Union and the United Kingdom. – mapped since the issue of late-stage thrombosis with drug – eluting stents came to light recently, interventional cardiologists have been reexamining play the valuable role of bare-metal stents in the treatment of coronary artery disease in many patients can said Joe Horn, president of Global Therapeutics.

Global Therapeutics also is developing a breakthrough drug-eluting stents technology using the GTX platform and an improved application of antisense gene from his partner, AVI BioPharma, Inc. treatment developed from Corvallis, Oregon, the proliferation of a gene known to the process inhibit induce restenosis, added Horn the clinical trial is in the in the third quarter of 2008 in Europe.Full Report results will and and publications in peer-reviewed settings.

– ENGAGE AF-TIMI 48: Investigation edoxaban once a day opposite warfarin in more than 16,500 AF Patients for prevention of stroke and non systemic embolism. ENGAGE AF-TIMI 48 started to Enrolment in late 2008. Patrinos ‘ released presentations be available Added Monday to.